Annexon 将来の成長

NasdaqGS:ANNX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	54	-149	-119	-162	6
12/31/2025	11	-159	-136	-177	7
12/31/2024	N/A	-127	-129	-95	7
9/30/2024	N/A	-118	-105	-105	N/A
6/30/2024	N/A	-115	-102	-102	N/A
3/31/2024	N/A	-121	-116	-116	N/A
12/31/2023	N/A	-134	-121	-121	N/A
9/30/2023	N/A	-141	-125	-125	N/A
6/30/2023	N/A	-143	-128	-127	N/A
3/31/2023	N/A	-145	-120	-119	N/A
12/31/2022	N/A	-142	-123	-116	N/A
9/30/2022	N/A	-145	-125	-117	N/A
6/30/2022	N/A	-145	-124	-116	N/A
3/31/2022	N/A	-140	-120	-113	N/A
12/31/2021	N/A	-130	-108	-106	N/A
9/30/2021	N/A	-116	-98	-97	N/A
6/30/2021	N/A	-103	-81	-81	N/A
3/31/2021	N/A	-84	-67	-67	N/A
12/31/2020	N/A	-70	-54	-53	N/A
9/30/2020	N/A	-56	-43	-43	N/A
6/30/2020	N/A	-45	-36	-36	N/A
3/31/2020	N/A	-42	-33	-32	N/A
12/31/2019	N/A	-38	-29	-28	N/A
9/30/2019	N/A	-34	-25	-24	N/A
6/30/2019	N/A	-28	-21	-21	N/A
3/31/2019	N/A	-23	-19	-19	N/A
12/31/2018	N/A	-18	-17	-17	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ANNX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ANNX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ANNX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ANNXの収益 ( 75.6% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: ANNXの収益 ( 75.6% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ANNXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Annexon 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target increased by 13% to US$16.40

Price target increased by 9.0% to US$15.17

Price target increased by 10% to US$15.60

Price target increased by 9.0% to US$15.33

Price target decreased by 18% to US$15.43

Price target decreased to US$18.71

Recent updates

CEO, President & Director exercised options to buy US$833k worth of stock.

Annexon, Inc. to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely

Annexon, Inc. Announces Management Appointments

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Annexon, Inc. Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

Annexon, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Price target increased by 13% to US$16.40

Annexon, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Annexon, Inc. Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome

New major risk - Share price stability

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Annexon, Inc. Presents New Neuro Protection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy

Annexon, Inc., Annual General Meeting, Jun 05, 2024

Annexon: Unforced Error Sullies Prospects

Price target increased by 9.0% to US$15.17

Annexon, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New minor risk - Insider selling

New major risk - Share price stability

Executive VP notifies of intention to sell stock

Annexon, Inc. has completed a Follow-on Equity Offering in the amount of $125.01642 million.

Annexon, Inc. has completed a Follow-on Equity Offering in the amount of $125.01642 million.

New major risk - Revenue and earnings growth

Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation

New minor risk - Market cap size

Price target increased by 10% to US$15.60

New major risk - Revenue and earnings growth

Price target increased by 9.0% to US$15.33

Annexon, Inc. Appoints Jamie Dananberg as Chief Medical Officer

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Price target decreased by 18% to US$15.43

Annexon, Inc. Announces Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Are Investors Undervaluing Annexon, Inc. (NASDAQ:ANNX) By 25%?

Annexon, Inc. Highlights Strategic Focus to Advance Four Complement Programs Through Late-Stage Development and Progress Across Three Therapeutic Franchises

Annexon, Inc. Announces Executive Changes

We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully

Price target decreased to US$18.71

Annexon started as a buy at Jefferies on market potential of candidates, data catalysts

Annexon: A First Take

Price target decreased to US$24.25

Annexon Biosciences GAAP EPS of -$0.96 misses by $0.02

Annexon, Inc. announced that it has received $130.475296 million in funding from a group of investors

Annexon, Inc. announced that it expects to receive $130.475296 million in funding from a group of investors

Annexon to raise $130M in stock and warrant offering

Annexon, Inc.(NasdaqGS:ANNX) dropped from Russell 2500 Index

Annexon, Inc. Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’S Disease

Price target decreased to US$30.80

CEO, President & Director recently bought US$147k worth of stock

We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate

Price target decreased to US$30.80

Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy

Price target decreased to US$34.20

Annexon, Inc. Announces Resignation of Sanjay Keswani as Executive Vice President and Chief Medical Officer

Annexon, Inc. Announces Resignation of Ricky Sun as Board Member

Annexon, Inc. Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Annexon Biosciences Announces Clinical and Preclinical Data Highlighting Potential of Complement-Targeting Programs at the 63rd ASH Annual Meeting & Exposition

CEO, President & Director exercised options to buy US$1.5m worth of stock.

Executive VP & Chief Scientific Officer Ted Yednock has left the company

Executive VP & Chief Scientific Officer exercised options and sold US$297k worth of stock

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Annexon, Inc Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion into New Autoantibody-driven Diseases

Annexon, Inc.(NasdaqGS:ANNX) dropped from Russell 2500 Growth Index

Executive VP & CFO exercised options and sold US$52k worth of stock

We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

Annexon, Inc. Announces Executive Changes

Independent Director has left the company